已收录 272639 条政策
 政策提纲
  • 暂无提纲
Gemcitabine in Bone Sarcoma Resistant to Doxorubicin-BasedChemotherapy
[摘要] Subjects and Methods:Seven patients with progressive localized ormetastatic chemo-resistant osteosarcoma were treated by gemcitabine.The protocolincluded gemcitabine 1000 mg/m2/w for 7 consecutive weeks, followed by 1 week rest. If no progression was observed,maintenance by gemcitabine 1000 mg/m2/w for 3 weeks every 28 days was given until failure was clinically or radiologically evident.Results.The true objective response rate was 0%. However, disease stabilization and clinical benefit response were observed in five patients (70%) for 13–96 weeks.Discussion.Postponing the inevitable death with a relatively non-toxic treatment, is, in our opinion, an important issue especially in young patients.Thus it may be justified and warranted to investigate the activity of gemcitabine in a larger groupof patients with bone sarcomas.
[发布日期]  [发布机构] 
[效力级别]  [学科分类] 肿瘤学
[关键词]  [时效性] 
   浏览次数:2      统一登录查看全文      激活码登录查看全文